Girentuximab-Zr-89 - Telix Pharmaceuticals

Drug Profile

Girentuximab-Zr-89 - Telix Pharmaceuticals

Alternative Names: 89Zr-girentuximab; 89Zr-TX250; TLX-250; Zirconium-89 girentuximab; Zr-89-girentuximab

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator WILEX AG
  • Developer Radbound University Nijmegen
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Natural killer cell stimulants; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Renal cell carcinoma

Most Recent Events

  • 15 Mar 2018 Telix Pharmaceuticals and Radboud University enter a research collaboration for development of Girentuximab-Zr-89
  • 14 Dec 2017 Telix Pharmaceuticals and Memorial Sloan Kettering Cancer Center (MSK) agree to use Girentuximab-Zr-89 (also known as TLX 250) as a tool for Cancer (Diagnosis)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top